



COMMUNICATION OF OTHER RELEVANT INFORMATION

ATRYS HEALTH, S.A.

15 de enero de 2026

In accordance with the provisions of Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as well as Article 227 and related provisions of Law 6/2023 of 17 March on Securities Markets and Investment Services, **Atryp Health, S.A.** (the “**Company**”) hereby announces the following:

In the disclosure of inside information published on 4 November 2025 (registration number 2981), the Company reported the execution of the share purchase agreement for the sale of the entire share capital of Aspy Global Services, S.A.U. to Grupo Echevarne (the “**Transaction**”), noting that completion of the Transaction was subject to the fulfilment of the following conditions precedent: (i) authorisation of the Transaction by the Spanish National Commission on Markets and Competition (CNMC); (ii) approval of the Transaction by the Company’s General Shareholders’ Meeting; and (iii) approval of the Transaction by the Company’s financing entities.

In the disclosure of other relevant information published on 12 December 2025 (registration number 38118), the Company reported that authorisation to the Transaction had been obtained from the CNMC.

The Company hereby informs that, once the remaining conditions precedent had been fulfilled, on 14 January 2026 the Company, as seller, and Grupo Echevarne, as purchaser, executed and completed the transfer of 100% of the shares of Aspy Global Services, S.A.U. and its subsidiaries in favour of Grupo Echevarne.

All funds received by the Company as consideration for the sale have been allocated to the full early repayment of the outstanding debt under the financing agreement (senior facilities agreement) entered into on 14 December 2021 in the amount of EUR 180 million.

Madrid, 15 January 2026

Doña María Antonia Isach Gabaldón

Chief Executive Officer